Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.00    -0.60 (-0.38%)
Bid:
156.40
Ask:
156.80
Spread: 0.40 (0.256%)
Market Cap: £891.97m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Trading update

14 Jan 2021 07:00

RNS Number : 6200L
Elementis PLC
14 January 2021
 

Elementis plc

Trading Update

Sequential revenue improvement, FY 20 adjusted operating profit $81-83m

Significant reduction in net debt, anticipated to be under $415m

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 31 December 2020.

Fourth quarter business performance

 

Fourth quarter revenue is expected to be ahead of the third quarter driven by improved volumes and largely stable pricing. Overall performance in the quarter is anticipated to be in line with management expectations, helped by tight cost management and supply chain efficiencies. As a result, adjusted operating profit for 2020 is expected to be $81-83m.

· Coatings has continued to perform well in Q4, albeit at lower levels than the prior year period, and remains on track to deliver improved operating margins versus the prior year.

 

· Personal Care sales remain materially lower than the prior year period in both Cosmetics and AP Actives, due to the continuation of COVID-19 related social and travel restrictions that have reduced consumption. Q4 performance is anticipated to be in line with Q3 levels. 

 

· Talc volumes continued to recover, driven by improved long-life plastic demand for automotive applications and resilience in coatings. As a result, Q4 revenue is expected to be ahead of the prior year period.

· Chromium demand has sequentially improved, driven by increased demand for industrial applications such as leather tanning and metal plating. As a result, Q4 revenue is anticipated to be broadly in line with the prior year period.

 

· Energy continues to experience very weak market conditions with rig counts and activity levels remaining subdued.

 

In the fourth quarter we have continued to deliver against our Innovation, Growth and Efficiency strategy. For full year 2020 we launched 12 new products, captured over $30m of new business and delivered $15m of in year cost savings.

For 2021, whilst our new business and innovation pipelines are encouraging, we continue to face temporary demand challenges from COVID-19, particularly in Personal Care where we expect performance will recover when social and travel restrictions are lifted. As a result of the recently announced closure of our plant in Charleston, West Virginia, we have made further progress underpinning $10m of supply chain cost efficiencies, and our new AP Actives plant in India remains on track for mid-2021 start up.

Liquidity and balance sheet

 

As result of tight working capital management and disciplined capital expenditure, net debt* at the end of 2020 is anticipated to be under $415m, representing a significant reduction from $454m at the start of the year.

 

Elementis has a proven cash generative business model, with average operating cash conversion above 90% over the last 3 years, and the Group continues to operate with ample liquidity, with over $300m immediately available through committed lending facilities.

 

 

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

 

Tulchan

Martin Robinson Tel: 020 7353 4200

David Allchurch

 

* Excluding IFRS 16 impact

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFZGMMRFGGMZM
Date   Source Headline
21st Jan 20257:00 amRNSTrading Update
16th Jan 20251:45 pmRNSHolding(s) in Company
2nd Jan 202510:06 amRNSTotal Voting Rights
24th Dec 20247:00 amRNSDirectorate Change
9th Dec 20245:05 pmRNSDirector/PDMR Shareholding
2nd Dec 202410:06 amRNSTotal Voting Rights
18th Nov 20247:00 amRNSChief Executive Succession
1st Nov 20249:54 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSThird Quarter Trading Update
11th Oct 202411:18 amRNSDirector/PDMR Shareholding
17th Sep 20248:50 amRNSDirector/PDMR Shareholding
2nd Sep 20249:31 amRNSBlock listing Interim Review
23rd Aug 202410:31 amRNSHolding(s) in Company
14th Aug 202410:53 amRNSAdditional Listing
9th Aug 20242:43 pmRNSHolding(s) in Company
2nd Aug 20245:44 pmRNSHolding(s) in Company
1st Aug 20243:10 pmRNSCorrection of dividend record date
1st Aug 20247:00 amRNSHalf-year Report
15th Jul 202410:59 amRNSHolding(s) in Company
30th May 202412:52 pmRNSDirector/PDMR Shareholding
29th May 20241:07 pmRNSDirector Declaration
8th May 202411:08 amRNSDirector/PDMR Shareholding
3rd May 202411:46 amRNSHolding(s) in Company
1st May 202410:06 amRNSTotal Voting Rights
30th Apr 202411:36 amRNSResult of AGM
30th Apr 20247:00 amRNSFirst quarter trading update
29th Apr 202412:13 pmRNSResponse to open letter from Gatemore
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.